Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q2 FY26 results · Jul–Sep 2025
Dr. Lal Path Labs reported revenue from operations of ₹730.60 crore (up 10.7% from Q2 FY25) and net profit of ₹152.20 crore (up 16.4% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 730.60 | 660.20 | +10.7% | 669.80 | +9.1% |
| Other income | 24.80 | 21.90 | +13.2% | 28.10 | −11.7% |
| Total income | 755.40 | 682.10 | +10.7% | 697.90 | +8.2% |
| Profit before tax | 203.60 | 183.10 | +11.2% | 181.10 | +12.4% |
| Net profit for the period | 152.20 | 130.80 | +16.4% | 134.00 | +13.6% |
| Attributable to shareholders of the company | 150.60 | 129.20 | +16.6% | 132.40 | +13.7% |
| EPS, basic (₹) | 18.05 | 15.52 | +16.3% | 15.88 | +13.7% |
| Net margin (%) | 20.8 | 19.8 | 20.0 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 699.60 | 583.90 | +19.8% | 640.70 | +9.2% |
| Other income | 22.80 | 22.00 | +3.6% | 26.30 | −13.3% |
| Total income | 722.40 | 605.90 | +19.2% | 667.00 | +8.3% |
| Profit before tax | 194.80 | 183.30 | +6.3% | 172.40 | +13.0% |
| Net profit for the period | 145.70 | 135.20 | +7.8% | 129.30 | +12.7% |
| EPS, basic (₹) | 17.46 | 16.24 | +7.5% | 15.51 | +12.6% |
| Net margin (%) | 20.8 | 23.2 | 20.2 |
Consolidated
- Filed with BSE
- 31 Oct 2025, 18:08 IST
- Board meeting
- 31 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Oct 2025, 18:08 IST
- Board meeting
- 31 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE